Search

Your search keyword '"Mikhailidis, Dimitri P."' showing total 719 results
Start Over Author "Mikhailidis, Dimitri P." Search Limiters Full Text
719 results on '"Mikhailidis, Dimitri P."'

1. New-Onset Diabetes Mellitus in COVID-19: A Scoping Review

Author

Pantea Stoian, Anca, Bica, Ioana-Cristina, Salmen, Teodor, Al Mahmeed, Wael, Al-Rasadi, Khalid, Al-Alawi, Kamila, Banach, Maciej, Banerjee, Yajnavalka, Ceriello, Antonio, Cesur, Mustafa, Cosentino, Francesco, Firenze, Alberto, Galia, Massimo, Goh, Su-Yen, Janez, Andrej, Kalra, Sanjay, Kapoor, Nitin, Kempler, Peter, Lessan, Nader, Lotufo, Paulo, Mikhailidis, Dimitri P., Nibali, Luigi, Papanas, Nikolaos, Powell-Wiley, Tiffany, Rizvi, Ali A., Sahebkar, Amirhossein, Santos, Raul D., Toth, Peter P., Viswanathan, Vijay, and Rizzo, Manfredi

Published
2024
Full Text
View/download PDF

2. Correction to: New-Onset Diabetes Mellitus in COVID-19: A Scoping Review

Author

Pantea Stoian, Anca, Bica, Ioana-Cristina, Salmen, Teodor, Al Mahmeed, Wael, Al-Rasadi, Khalid, Al-Alawi, Kamila, Banach, Maciej, Banerjee, Yajnavalka, Ceriello, Antonio, Cesur, Mustafa, Cosentino, Francesco, Firenze, Alberto, Galia, Massimo, Goh, Su-Yen, Janez, Andrej, Kalra, Sanjay, Kapoor, Nitin, Kempler, Peter, Lessan, Nader, Lotufo, Paulo, Mikhailidis, Dimitri P., Nibali, Luigi, Papanas, Nikolaos, Powell-Wiley, Tiffany, Rizvi, Ali A., Sahebkar, Amirhossein, Santos, Raul D., Toth, Peter P., Viswanathan, Vijay, and Rizzo, Manfredi

Published
2024
Full Text
View/download PDF

3. Prevalence of statin intolerance: a meta-analysis

Author

Bytyçi, Ibadete, Penson, Peter E, Mikhailidis, Dimitri P, Wong, Nathan D, Hernandez, Adrian V, Sahebkar, Amirhossein, Thompson, Paul D, Mazidi, Mohsen, Rysz, Jacek, Pella, Daniel, Reiner, Željko, Toth, Peter P, and Banach, Maciej

Subjects
Heart Disease, Cardiovascular, Prevention, Atherosclerosis, Female, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipids, Male, Prevalence, Randomized Controlled Trials as Topic, Risk Factors, Cardiovascular disease, Risk factors, Statin intolerance, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Cardiovascular System & Hematology
Abstract

AimsStatin intolerance (SI) represents a significant public health problem for which precise estimates of prevalence are needed. Statin intolerance remains an important clinical challenge, and it is associated with an increased risk of cardiovascular events. This meta-analysis estimates the overall prevalence of SI, the prevalence according to different diagnostic criteria and in different disease settings, and identifies possible risk factors/conditions that might increase the risk of SI.Methods and resultsWe searched several databases up to 31 May 2021, for studies that reported the prevalence of SI. The primary endpoint was overall prevalence and prevalence according to a range of diagnostic criteria [National Lipid Association (NLA), International Lipid Expert Panel (ILEP), and European Atherosclerosis Society (EAS)] and in different disease settings. The secondary endpoint was to identify possible risk factors for SI. A random-effects model was applied to estimate the overall pooled prevalence. A total of 176 studies [112 randomized controlled trials (RCTs); 64 cohort studies] with 4 143 517 patients were ultimately included in the analysis. The overall prevalence of SI was 9.1% (95% confidence interval 8.0-10%). The prevalence was similar when defined using NLA, ILEP, and EAS criteria [7.0% (6.0-8.0%), 6.7% (5.0-8.0%), 5.9% (4.0-7.0%), respectively]. The prevalence of SI in RCTs was significantly lower compared with cohort studies [4.9% (4.0-6.0%) vs. 17% (14-19%)]. The prevalence of SI in studies including both primary and secondary prevention patients was much higher than when primary or secondary prevention patients were analysed separately [18% (14-21%), 8.2% (6.0-10%), 9.1% (6.0-11%), respectively]. Statin lipid solubility did not affect the prevalence of SI [4.0% (2.0-5.0%) vs. 5.0% (4.0-6.0%)]. Age [odds ratio (OR) 1.33, P = 0.04], female gender (OR 1.47, P = 0.007), Asian and Black race (P 4 million patients, the prevalence of SI is low when diagnosed according to international definitions. These results support the concept that the prevalence of complete SI might often be overestimated and highlight the need for the careful assessment of patients with potential symptoms related to SI.

Published
2022

4. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the International Lipid Expert Panel (ILEP).

Author

Penson, Peter E, Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P, Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P, Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung-I, Mancini, GB John, von Haehling, Stephan, Banach, Maciej, and International Lipid Expert Panel (ILEP)

Subjects
International Lipid Expert Panel, Muscles, Humans, Muscular Diseases, Lipids, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Nocebo Effect, Drucebo effect, Nocebo effect, SAMS, Statin intolerance, Pain Research, Patient Safety, Clinical Research, 6.1 Pharmaceuticals, 7.3 Management and decision making, Management of diseases and conditions, Evaluation of treatments and therapeutic interventions, Musculoskeletal, Physiology, Clinical Sciences, Human Movement and Sports Sciences
Abstract

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.

Published
2022

5. Artificial intelligence for cardiovascular disease risk assessment in personalised framework: a scoping review

Author

Singh, Manasvi, Kumar, Ashish, Khanna, Narendra N., Laird, John R., Nicolaides, Andrew, Faa, Gavino, Johri, Amer M., Mantella, Laura E., Fernandes, Jose Fernandes E., Teji, Jagjit S., Singh, Narpinder, Fouda, Mostafa M., Singh, Rajesh, Sharma, Aditya, Kitas, George, Rathore, Vijay, Singh, Inder M., Tadepalli, Kalyan, Al-Maini, Mustafa, Isenovic, Esma R., Chaturvedi, Seemant, Garg, Deepak, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Viswanathan, Vijay, Kalra, Manudeep K., Ruzsa, Zoltan, Saba, Luca, Laine, Andrew F., Bhatt, Deepak L., and Suri, Jasjit S.

Published
2024
Full Text
View/download PDF

7. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Acosta, Julio, Al-Khnifsawi, Mutaz, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bajraktari, Gani, Banach, Maciej, Gouni-Berthold, Ioanna, Bhaskar, Sonu, Bielecka-Dąbrowa, Agata, Bjelakovic, Bojko, Bruckert, Eric, Bytyçi, Ibadete, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Chlebus, Krzysztof, Collet, Xavier, Daccord, Magdalena, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Kallel, Amani, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Latkovskis, Gustavs, John Mancini, G.B., David Marais, A., Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mikhailidis, Dimitri P., Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Mitkovskaya, Natalya P., Moriarty, Patrick M., Mohammad Nabavi, Seyed, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulioniene, Zaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Radenkovic, Dina, Rakowski, Michał, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Serban, Maria-Corina, Shehab, Abdullah M.A, Shek, Aleksandr B., Sirtori, Cesare R., Stefanutti, Claudia, Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Valdivielso, Pedro, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I, Zhisheng, Jiang, Zirlik, Andreas, Colletti, Alessandro, Mancini, John, Marais, David, Moriarty, Patrick, and Cicero, Arrigo Francesco Giuseppe

Published
2023
Full Text
View/download PDF

8. Dietary patterns, plasma vitamins and Trans fatty acids are associated with peripheral artery disease

Author

Mazidi, Mohsen, Wong, Nathan D, Katsiki, Niki, Mikhailidis, Dimitri P, and Banach, Maciej

Subjects
Biomedical and Clinical Sciences, Nutrition and Dietetics, Prevention, Cardiovascular, Nutrition, Cancer, Complementary and Integrative Health, Clinical Research, Metabolic and endocrine, Adult, Aged, Ankle Brachial Index, Dietary Fats, Diterpenes, Fatty Acids, Unsaturated, Feeding Behavior, Female, Humans, Logistic Models, Male, Middle Aged, Nutrition Surveys, Odds Ratio, Oleic Acid, Peripheral Arterial Disease, Principal Component Analysis, Retinyl Esters, United States, Vitamin A, Vitamin D, Peripheral artery disease, Dietary patterns, Vitamins, Trans fatty acids, Other Information and Computing Sciences, Medical Biochemistry and Metabolomics, Nutrition & Dietetics, Medical biochemistry and metabolomics, Nutrition and dietetics
Abstract

BackgroundTo investigate the association between dietary patterns (DP), plasma vitamins and trans fatty acids (TFAs) with the likelihood of peripheral artery disease (PAD).MethodsNational Health and Nutrition Examination Survey (NHANES) data for the years 1999-2002 were used. PAD was diagnosed by ankle brachial index assessment. Plasma concentrations of vitamins were measured using high performance liquid chromatography. Vitamin D levels were measured by radioimmunoassay. Analysis of covariance, principal components analysis (PCA) and adjusted logistic regression were applied, accounting for the survey design and sample weights.ResultsOf the 4864 eligible participants, 2482 (51.0%) were men and 269 (5.5%) had prevalent PAD. PCA uncovered three DPs which accounted for 56.8% of the variance in dietary nutrients consumption including DP1 (fatty acids and cholesterol), DP2 (minerals, vitamins and fiber), and DP3 (polyunsaturated fatty acids [PUFA]). PAD patients had a significantly higher serum concentrations of trans 9-octadecenoic acid and trans 9, trans 12-octadienoic acid as well as lower plasma levels of vitamin D, retinol, retinyl stearate and retinyl palmitate (p

Published
2017

10. Carotid Plaque-RADS: A Novel Stroke Risk Classification System

Author

Brain, MS Radiologie, Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N., Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stavros K., Yang, Qi, Paraskevas, Kosmas I., Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mahmud, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, H. Rolf, Naylor, Ross, Faa, Gavino, Suri, Jasjit S., Costello, Justin, Auer, Dorothee P., Mcnally, J. Scott, Bonati, Leo H., Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A., Kooi, M. Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P., Mandell, Daniel M., Benson, John C., van Dam-Nolen, Dianne H.K., Kopczak, Anna, Song, Jae W., Gupta, Ajay, DeMarco, J. Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Thomas S., Brown, Martin, Moody, Alan R., Libby, Peter, Schindler, Andreas, Saam, Tobias, Brain, MS Radiologie, Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N., Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stavros K., Yang, Qi, Paraskevas, Kosmas I., Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mahmud, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, H. Rolf, Naylor, Ross, Faa, Gavino, Suri, Jasjit S., Costello, Justin, Auer, Dorothee P., Mcnally, J. Scott, Bonati, Leo H., Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A., Kooi, M. Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P., Mandell, Daniel M., Benson, John C., van Dam-Nolen, Dianne H.K., Kopczak, Anna, Song, Jae W., Gupta, Ajay, DeMarco, J. Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Thomas S., Brown, Martin, Moody, Alan R., Libby, Peter, Schindler, Andreas, and Saam, Tobias

Published
2024

11. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans Henning, Gloviczki, Peter, White, Christopher J., Zorgeenheid Vaatchirurgie Medisch, Circulatory Health, Regenerative Medicine and Stem Cells, Paraskevas, Kosmas I., Mikhailidis, Dimitri P., Ringleb, Peter Arthur, Brown, Martin M., Dardik, Alan, Poredos, Pavel, Gray, William A., Nicolaides, Andrew N., Lal, Brajesh K., Mansilha, Armando, Antignani, Pier Luigi, de Borst, Gert J., Cambria, Richard P., Loftus, Ian M., Lavie, Carl J., Blinc, Ales, Lyden, Sean P., Matsumura, Jon S., Jezovnik, Mateja K., Bacharach, J. Michael, Meschia, James F., Clair, Daniel G., Zeebregts, Clark J., Lanza, Gaetano, Capoccia, Laura, Spinelli, Francesco, Liapis, Christos D., Jawien, Arkadiusz, Parikh, Sahil A., Svetlikov, Alexei, Menyhei, Gabor, Davies, Alun H., Musialek, Piotr, Roubin, Gary, Stilo, Francesco, Sultan, Sherif, Proczka, Robert M., Faggioli, Gianluca, Geroulakos, George, Fernandes e Fernandes, Jose, Ricco, Jean Baptiste, Saba, Luca, Secemsky, Eric A., Pini, Rodolfo, Myrcha, Piotr, Rundek, Tatjana, Martinelli, Ombretta, Kakkos, Stavros K., Sachar, Ravish, Goudot, Guillaume, Schlachetzki, Felix, Lavenson, George S., Ricci, Stefano, Topakian, Raffi, Millon, Antoine, Di Lazzaro, Vincenzo, Silvestrini, Mauro, Chaturvedi, Seemant, Eckstein, Hans Henning, Gloviczki, Peter, and White, Christopher J.

Published
2024

12. Carotid Plaque-RADS, a novel stroke risk classification system

Author

Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N, Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stravos, Yang, Qi, Paraskevas, Kosmas I, Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mamood, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, Rolf H, Naylor, Ross, Faa, Gavino, Suri, Jasjit S, Costello, Justin, Auer, Dorothee P, McNally, Scott, Bonati, Leo H, Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A, Kooi, M Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P, Mandell, Danny M, Benson, John, van Dam-Nolen, Dianne, Kopczak, Anna, Song, Jae, Gupta, Ajay, DeMarco, J Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Tom, Brown, Martin, Moody, Alan R, Libby, Peter, Schindler, Andreas, Et al., Saba, Luca, Cau, Riccardo, Murgia, Alessandro, Nicolaides, Andrew N, Wintermark, Max, Castillo, Mauricio, Staub, Daniel, Kakkos, Stravos, Yang, Qi, Paraskevas, Kosmas I, Yuan, Chun, Edjlali, Myriam, Sanfilippo, Roberto, Hendrikse, Jeroen, Johansson, Elias, Mossa-Basha, Mamood, Balu, Niranjan, Dichgans, Martin, Saloner, David, Bos, Daniel, Jager, Rolf H, Naylor, Ross, Faa, Gavino, Suri, Jasjit S, Costello, Justin, Auer, Dorothee P, McNally, Scott, Bonati, Leo H, Nardi, Valentina, van der Lugt, Aad, Griffin, Maura, Wasserman, Bruce A, Kooi, M Eline, Gillard, Jonathan, Lanzino, Giuseppe, Mikhailidis, Dimitri P, Mandell, Danny M, Benson, John, van Dam-Nolen, Dianne, Kopczak, Anna, Song, Jae, Gupta, Ajay, DeMarco, J Kevin, Chaturvedi, Seemant, Virmani, Renu, Hatsukami, Tom, Brown, Martin, Moody, Alan R, Libby, Peter, Schindler, Andreas, and Et al.

Abstract

Background: Carotid artery atherosclerosis is highly prevalent in the general population and is a well-established risk factor for acute ischemic stroke. Although the morphological characteristics of vulnerable plaques are well recognized, there is a lack of consensus in reporting and interpreting carotid plaque features. Objectives: The aim of this paper is to establish a consistent and comprehensive approach for imaging and reporting carotid plaque by introducing the Plaque–RADS (Reporting and Data System) score. Methods: A panel of experts recognized the necessity to develop a classification system for carotid plaque and its defining characteristics. Using a multimodality analysis approach, the Plaque-RADS categories were established through consensus, drawing on existing published reports. Results: The authors present a universal classification that is applicable to both researchers and clinicians. The Plaque-RADS score offers a morphological assessment in addition to the prevailing quantitative parameter of “stenosis.” The Plaque-RADS score spans from grade 1 (indicating complete absence of plaque) to grade 4 (representing complicated plaque). Accompanying visual examples are included to facilitate a clear understanding of the Plaque-RADS categories. Conclusions: Plaque-RADS is a standardized and reliable system of reporting carotid plaque composition and morphology via different imaging modalities, such as ultrasound, computed tomography, and magnetic resonance imaging. This scoring system has the potential to help in the precise identification of patients who may benefit from exclusive medical intervention and those who require alternative treatments, thereby enhancing patient care. A standardized lexicon and structured reporting promise to enhance communication between radiologists, referring clinicians, and scientists.

Published
2024

13. Effects of Quercetin on Blood Pressure: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Author

Serban, Maria‐Corina, Sahebkar, Amirhossein, Zanchetti, Alberto, Mikhailidis, Dimitri P, Howard, George, Antal, Diana, Andrica, Florina, Ahmed, Ali, Aronow, Wilbert S, Muntner, Paul, Lip, Gregory YH, Graham, Ian, Wong, Nathan, Rysz, Jacek, Banach, Maciej, and Group, for the Lipid and Blood Pressure Meta‐analysis Collaboration

Subjects
Prevention, Nutrition, Complementary and Integrative Health, Cardiovascular, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antioxidants, Blood Pressure, Humans, Quercetin, Randomized Controlled Trials as Topic, blood pressure, flavonoids, high blood pressure, hypertension, lipids, meta-analysis, nutrition, quercetin, Lipid and Blood Pressure Meta‐analysis Collaboration (LBPMC) Group, meta‐analysis, Cardiorespiratory Medicine and Haematology
Abstract

Quercetin, the most abundant dietary flavonol, has antioxidant effects in cardiovascular disease, but the evidence regarding its effects on blood pressure (BP) has not been conclusive. We assessed the impact of quercetin on BP through a systematic review and meta-analysis of available randomized controlled trials. We searched PUBMED, Cochrane Library, Scopus, and EMBASE up to January 31, 2015 to identify placebo-controlled randomized controlled trials investigating the effect of quercetin on BP. Meta-analysis was performed using either a fixed-effects or random-effect model according to I(2) statistic. Effect size was expressed as weighted mean difference (WMD) and 95% CI. Overall, the impact of quercetin on BP was reported in 7 trials comprising 9 treatment arms (587 patients). The results of the meta-analysis showed significant reductions both in systolic BP (WMD: -3.04 mm Hg, 95% CI: -5.75, -0.33, P=0.028) and diastolic BP (WMD: -2.63 mm Hg, 95% CI: -3.26, -2.01, P500 mg/day. Further studies are necessary to investigate the clinical relevance of these results and the possibility of quercetin application as an add-on to antihypertensive therapy.

Published
2016

14. Are We Using Ezetimibe As Much As We Should?

Author

Manolis, Antonis A, Manolis, Theodora A, Mikhailidis, Dimitri P, and Manolis, Antonis S

Subjects
EZETIMIBE, LDL cholesterol, STATINS (Cardiovascular agents), LOW density lipoproteins, CONTRAST media
Abstract

Lipid-lowering therapies, particularly non-statin regimens, are underutilized as ~2/3 of patients with atherosclerotic cardiovascular (CV) disease (CVD) are not optimally managed, and do not attain target low-density lipoprotein cholesterol (LDL-C) concentrations, despite statin treatment. Statins have been the mainstay of hypolipidemic therapies; however, they are plagued by adverse effects, which have partly hindered their more widespread use. Ezetimibe is often the first added mode of treatment to attain LDL-C goals as it is efficacious and also allows the use of a smaller dose of statin, while the need for more expensive therapies is obviated. We herein provide a comprehensive review of the effects of ezetimibe in lipid lowering and reducing CV events and improving outcomes. Of the hypolipidemic therapies, oral ezetimibe, in contrast to newer agents, is the most convenient and/or affordable regimen to be utilized as mono- or combined therapy supported by data from CV outcomes studies attesting to its efficacy in reducing CVD risk and events. When combined with a statin, the statin dose could be lower, thus curtailing side-effects, while the hypolipidemic effect is enhanced (by ~20%) as the percentage of patients with target level LDL-C (<70 mg/dL) is higher with combined treatment versus a high-intensity statin. Ezetimibe could also serve as an alternative treatment in cases of statin intolerance. In conclusion, ezetimibe has an excellent safety/tolerability profile; it is the first added treatment to a statin that can attain LDL-C targets. In the combined therapy, the hypolipidemic effect is enhanced while the dose of statin could be lower, thus limiting the occurrence of side-effects. Ezetimibe could also serve as an alternative mode of treatment in cases of statin intolerance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. An international, multispecialty, expert-based Delphi Consensus document on controversial issues in the management of patients with asymptomatic and symptomatic carotid stenosis

Author

Paraskevas, Kosmas I., primary, Mikhailidis, Dimitri P., additional, Ringleb, Peter Arthur, additional, Brown, Martin M., additional, Dardik, Alan, additional, Poredos, Pavel, additional, Gray, William A., additional, Nicolaides, Andrew N., additional, Lal, Brajesh K., additional, Mansilha, Armando, additional, Antignani, Pier Luigi, additional, de Borst, Gert J., additional, Cambria, Richard P., additional, Loftus, Ian M., additional, Lavie, Carl J., additional, Blinc, Ales, additional, Lyden, Sean P., additional, Matsumura, Jon S., additional, Jezovnik, Mateja K., additional, Bacharach, J. Michael, additional, Meschia, James F., additional, Clair, Daniel G., additional, Zeebregts, Clark J., additional, Lanza, Gaetano, additional, Capoccia, Laura, additional, Spinelli, Francesco, additional, Liapis, Christos D., additional, Jawien, Arkadiusz, additional, Parikh, Sahil A., additional, Svetlikov, Alexei, additional, Menyhei, Gabor, additional, Davies, Alun H., additional, Musialek, Piotr, additional, Roubin, Gary, additional, Stilo, Francesco, additional, Sultan, Sherif, additional, Proczka, Robert M., additional, Faggioli, Gianluca, additional, Geroulakos, George, additional, Fernandes e Fernandes, Jose, additional, Ricco, Jean-Baptiste, additional, Saba, Luca, additional, Secemsky, Eric A., additional, Pini, Rodolfo, additional, Myrcha, Piotr, additional, Rundek, Tatjana, additional, Martinelli, Ombretta, additional, Kakkos, Stavros K., additional, Sachar, Ravish, additional, Goudot, Guillaume, additional, Schlachetzki, Felix, additional, Lavenson, George S., additional, Ricci, Stefano, additional, Topakian, Raffi, additional, Millon, Antoine, additional, Di Lazzaro, Vincenzo, additional, Silvestrini, Mauro, additional, Chaturvedi, Seemant, additional, Eckstein, Hans-Henning, additional, Gloviczki, Peter, additional, and White, Christopher J., additional

Published
2023
Full Text
View/download PDF

16. Recent advances and controversial issues in the optimal management of asymptomatic carotid stenosis

Author

Paraskevas, Kosmas I., primary, Brown, Martin M., additional, Lal, Brajesh K., additional, Myrcha, Piotr, additional, Lyden, Sean P., additional, Schneider, Peter A., additional, Poredos, Pavel, additional, Mikhailidis, Dimitri P., additional, Secemsky, Eric A., additional, Musialek, Piotr, additional, Mansilha, Armando, additional, Parikh, Sahil A., additional, Silvestrini, Mauro, additional, Lavie, Carl J., additional, Dardik, Alan, additional, Blecha, Matthew, additional, Liapis, Christos D., additional, Zeebregts, Clark J., additional, Nederkoorn, Paul J., additional, Poredos, Peter, additional, Gurevich, Victor, additional, Jawien, Arkadiusz, additional, Lanza, Gaetano, additional, Gray, William A., additional, Gupta, Ajay, additional, Svetlikov, Alexei V., additional, Fernandes e Fernandes, Jose, additional, Nicolaides, Andrew N., additional, White, Christopher J., additional, Meschia, James F., additional, Cronenwett, Jack L., additional, Schermerhorn, Marc L., additional, and AbuRahma, Ali F., additional

Published
2023
Full Text
View/download PDF

17. Carotid Plaque-RADS, a novel stroke risk classification system

Author

Saba, Luca, primary, Cau, Riccardo, additional, Murgia, Alessandro, additional, Nicolaides, Andrew N., additional, Wintermark, Max, additional, Castillo, Mauricio, additional, Staub, Daniel, additional, Kakkos, Stravos, additional, Yang, Qi, additional, Paraskevas, Kosmas I., additional, Yuan, Chun, additional, Edjlali, Myriam, additional, Sanfilippo, Roberto, additional, Hendrikse, Jeroen, additional, Johansson, Elias, additional, Mossa-Basha, Mamood, additional, Balu, Niranjan, additional, Dichgans, Martin, additional, Saloner, David, additional, Bos, Daniel, additional, Jager, Rolf H., additional, Naylor, Ross, additional, Faa, Gavino, additional, Suri, Jasjit S., additional, Costello, Justin, additional, Auer, Dorothee P., additional, McNally, Scott, additional, Bonati, Leo H., additional, Nardi, Valentina, additional, van der Lugt, Aad, additional, Griffin, Maura, additional, Wasserman, Bruce A., additional, Kooi, M. Eline, additional, Gillard, Jonathan, additional, Lanzino, Giuseppe, additional, Mikhailidis, Dimitri P., additional, Mandell, Danny M., additional, Benson, John, additional, van Dam-Nolen, Dianne, additional, Kopczak, Anna, additional, Song, Jae, additional, Gupta, Ajay, additional, DeMarco, J. Kevin, additional, Chaturvedi, Seemant, additional, Virmani, Renu, additional, Hatsukami, Tom, additional, Brown, Martin, additional, Moody, Alan R., additional, Libby, Peter, additional, Schindler, Andreas, additional, and Saam, Tobias, additional

Published
2023
Full Text
View/download PDF

18. The Role of Nutraceuticals in Statin Intolerant Patients

Author

Banach, Maciej, Patti, Angelo Maria, Giglio, Rosaria Vincenza, Cicero, Arrigo F.G., Atanasov, Atanas G., Bajraktari, Gani, Bruckert, Eric, Descamps, Olivier, Djuric, Dragan M., Ezhov, Marat, Fras, Zlatko, von Haehling, Stephan, Katsiki, Niki, Langlois, Michel, Latkovskis, Gustavs, Mancini, G.B. John, Mikhailidis, Dimitri P., Mitchenko, Olena, Moriarty, Patrick M., Muntner, Paul, Nikolic, Dragana, Panagiotakos, Demosthenes B., Paragh, Gyorgy, Paulweber, Bernhard, Pella, Daniel, Pitsavos, Christos, Reiner, Željko, Rosano, Giuseppe M.C., Rosenson, Robert S., Rysz, Jacek, Sahebkar, Amirhossein, Serban, Maria-Corina, Vinereanu, Dragos, Vrablík, Michal, Watts, Gerald F., Wong, Nathan D., and Rizzo, Manfredi

Published
2018
Full Text
View/download PDF

20. Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview

Author

Telci Caklili,Ozge, Cesur,Mustafa, Mikhailidis,Dimitri P, and Rizzo,Manfredi

Subjects
Diabetes, Metabolic Syndrome and Obesity
Abstract

Ozge Telci Caklili,1 Mustafa Cesur,2 Dimitri P Mikhailidis,3 Manfredi Rizzo4 1Department of Endocrinology and Metabolism, Faculty of Medicine, University of Istanbul, Istanbul, Türkiye; 2Department of Endocrinology and Metabolism, Ankara Guven University Hospital, Ankara, Türkiye; 3Department of Clinical Biochemistry and Department of Surgical Biotechnology, Division of Surgery and Interventional Science, Medical School, University College London (UCL), London, UK; 4School of Medicine, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (Promise), University of Palermo, Palermo, ItalyCorrespondence: Manfredi Rizzo, School of Medicine, Promise Department, University of Palermo, Via del Vespro 141, Palermo, 90127, Italy, Tel/Fax +39 091 655-2945, Email manfredi.rizzo@unipa.itAbstract: Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease.Keywords: obesity, drugs, liraglutide, semaglutide, tirzepatide, orlistat, phentermine/topiramate, bupropion/naltrexone

Published
2023

22. Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP)

Author

Rizzo, Manfredi, primary, Colletti, Alessandro, additional, Penson, Peter E., additional, Katsiki, Niki, additional, Mikhailidis, Dimitri P., additional, Toth, Peter P., additional, Gouni-Berthold, Ioanna, additional, Mancini, John, additional, Marais, David, additional, Moriarty, Patrick, additional, Ruscica, Massimiliano, additional, Sahebkar, Amirhossein, additional, Vinereanu, Dragos, additional, Cicero, Arrigo Francesco Giuseppe, additional, Banach, Maciej, additional, Acosta, Julio, additional, Al-Khnifsawi, Mutaz, additional, Alnouri, Fahad, additional, Amar, Fahma, additional, Atanasov, Atanas G., additional, Bajraktari, Gani, additional, Bhaskar, Sonu, additional, Bielecka-Dąbrowa, Agata, additional, Bjelakovic, Bojko, additional, Bruckert, Eric, additional, Bytyçi, Ibadete, additional, Cafferata, Alberto, additional, Ceska, Richard, additional, Cicero, Arrigo F.G., additional, Chlebus, Krzysztof, additional, Collet, Xavier, additional, Daccord, Magdalena, additional, Descamps, Olivier, additional, Djuric, Dragan, additional, Durst, Ronen, additional, Ezhov, Marat V., additional, Fras, Zlatko, additional, Gaita, Dan, additional, Hernandez, Adrian V., additional, Jones, Steven R., additional, Jozwiak, Jacek, additional, Kakauridze, Nona, additional, Kallel, Amani, additional, Khera, Amit, additional, Kostner, Karam, additional, Kubilius, Raimondas, additional, Latkovskis, Gustavs, additional, John Mancini, G.B., additional, David Marais, A., additional, Martin, Seth S., additional, Martinez, Julio Acosta, additional, Mazidi, Mohsen, additional, Mirrakhimov, Erkin, additional, Miserez, Andre R., additional, Mitchenko, Olena, additional, Mitkovskaya, Natalya P., additional, Moriarty, Patrick M., additional, Mohammad Nabavi, Seyed, additional, Nair, Devaki, additional, Panagiotakos, Demosthenes B., additional, Paragh, György, additional, Pella, Daniel, additional, Petrulioniene, Zaneta, additional, Pirro, Matteo, additional, Postadzhiyan, Arman, additional, Puri, Raman, additional, Reda, Ashraf, additional, Reiner, Željko, additional, Radenkovic, Dina, additional, Rakowski, Michał, additional, Riadh, Jemaa, additional, Richter, Dimitri, additional, Rizzo, Manfredi, additional, Serban, Maria-Corina, additional, Shehab, Abdullah M.A, additional, Shek, Aleksandr B., additional, Sirtori, Cesare R., additional, Stefanutti, Claudia, additional, Tomasik, Tomasz, additional, Viigimaa, Margus, additional, Valdivielso, Pedro, additional, Vohnout, Branislav, additional, von Haehling, Stephan, additional, Vrablik, Michal, additional, Wong, Nathan D., additional, Yeh, Hung-I, additional, Zhisheng, Jiang, additional, and Zirlik, Andreas, additional

Published
2023
Full Text
View/download PDF

23. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies.

Author

Krzemień, Paweł, Kasperczyk, Sławomir, Banach, Maciej, Kasperczyk, Aleksandra, Dobrakowski, Michał, Tomasik, Tomasz, Windak, Adam, Mastej, Mirosław, Catapano, Alberico, Ray, Kausik K., Mikhailidis, Dimitri P., Toth, Peter P., Howard, George, Lip, Gregory Y. H., Tomaszewski, Maciej, Charchar, Fadi J., Sattar, Naveed, Williams, Bryan, MacDonald, Thomas M., and Penson, Peter E.

Subjects
OXIDATIVE stress, OXIDANT status, FACTOR analysis, AUTOANTIBODIES, REACTIVE oxygen species
Abstract

Introduction: Oxidative stress is one of many factors suspected to promote antinuclear autoantibody (ANA) formation. Reactive oxygen species can induce changes in the antigenic structure of macromolecules, causing the immune system to treat them as "neo-antigens" and start production of autoantibodies. This study was designed to evaluate the relationship between oxidative stress markers, lifestyle factors and the detection of ANA. Material and methods: We examined measures of oxidative stress indices of free-radical damage to lipids and proteins, such as total oxidant status (TOS), concentration of protein thiol groups (PSH), and malondialdehyde (MDA), activity of superoxide dismutase (SOD) in 1731 serum samples. The parameters of the non-enzymatic antioxidant system, such as total antioxidant status (TAS) and uric acid (UA) concentration, were also measured and the oxidative stress index (OSI-index) was calculated. All samples were tested for the presence of ANA using an indirect immunofluorescence assay (IIFA). Results: The presence of ANA in women was associated with lower physical activity (p = 0.036), less frequent smoking (p = 0.007) and drinking of alcohol (p = 0.024) accompanied by significant changes in SOD isoenzymes activity (p < 0.001) and a higher uric acid (UA) concentration (p < 0.001). In ANA positive males we observed lower concentrations of PSH (p = 0.046) and increased concentrations of MDA (p = 0.047). Conclusions: The results indicate that local oxidative stress may be associated with increased probability of ANA formation in a sex-specific manner. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

26. Metabolic syndrome is associated with similar long-term prognosis in those living with and without obesity : an analysis of 45 615 patients from the nationwide LIPIDOGRAM 2004-2015 studies

Author

Osadnik, Kamila, Osadnik, Tadeusz, Gierlotka, Marek, Windak, Adam, Tomasik, Tomasz, Mastej, Mirosław, Kuras, Agnieszka, Jóźwiak, Kacper, Penson, Peter E., Lip, Gregory Y.H., Mikhailidis, Dimitri P., Toth, Peter P., Catapano, Alberico L., Ray, Kausik K., Howard, George, Tomaszewski, Maciej, Charchar, Fadi J., Sattar, Naveed, Williams, Bryan, MacDonald, Thomas M., Banach, Maciej, and Jóźwiak, Jacek

Published
2023

30. The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper.

Author

Bielecka-Dabrowa, Agata, Banach, Maciej, Wittczak, Andrzej, Cicero, Arrigo F. G., Kallel, Amani, Kubilius, Raimondas, Mikhailidis, Dimitri P., Sahebkar, Amirhossein, Stoian, Anca Pantea, Vinereanu, Dragos, Penson, Peter E., and von Haehling, Stephan

Subjects
MYOCARDIUM, HEART failure, HEART failure patients, FUNCTIONAL foods, SKELETAL muscle, LEGAL evidence
Abstract

Muscle wasting is one of the main causes for exercise intolerance and ventilatory inefficiency in patients with heart failure and a strong predictor of frailty and reduced survival. The prevalence of sarcopenia is at least 20% in patients with heart failure. Patients with heart failure often have subclinical systemic inflammation, which may exert sustained effects on skeletal muscle. Besides exercise, nutrition should also be carefully evaluated as an appropriate diet with selected nutraceuticals may be able to stimulate muscle anabolism and inhibit muscle catabolism. This review summarizes the epidemiological and clinical trial evidence supporting the recommendations for the use of nutraceuticals with anti-inflammatory properties in heart failure and provides an overview of the state of the evidence for nutraceutical supplementation to prevent and/or mitigate heart failure muscle wasting. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

31. Novel Anti-obesity Therapies and their Different Effects and Safety Profiles: A Critical Overview.

Author

Caklili, Ozge Telci, Cesur, Mustafa, Mikhailidis, Dimitri P, and Rizzo, Manfredi

Subjects
BUPROPION, NALTREXONE, TOPIRAMATE, SEMAGLUTIDE, ORLISTAT, HIV prevention
Abstract

Obesity has become an epidemic and a worldwide problem and its treatment is ever-evolving. Apart from diet and exercise, medication and surgery are other options. After disappointing side effects of various obesity drugs, new treatments showed promising results. This review discusses the following anti-obesity drugs: liraglutide, semaglutide, tirzepatide, orlistat, as well as the phentermine/topiramate and bupropion/naltrexone combinations. These drugs have been approved by the Food and Drug Administration (FDA) for weight reduction except for tirzepatide which is still under evaluation. Efficacy and tolerable safety profiles of some of these drugs contribute to the management of obesity and reduce the complications associated with this chronic disease. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. The effect of bergamot on dyslipidemia

Author

Giglio, Rosaria Vincenza, Patti, Angelo Maria, Nikolic, Dragana, Li Volti, Giovanni, Rasadi, Khalid Al-, Katsiki, Niki, Mikhailidis, Dimitri P., Montalto, Giuseppe, Ivanova, Ekaterina, Orekhov, Alexander N., and Rizzo, Manfredi

Subjects
Bitter orange -- Usage -- Health aspects, Dyslipidemias -- Care and treatment, Biological sciences, Health, Science and technology
Abstract

ABSTRACT Background: Statins are the most common used lipid lowering drugs but they may cause adverse effects and despite their well-established therapeutic benefits residual cardiovascular (CV) risk remains. The use [...]

Published
2016
Full Text
View/download PDF

35. Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients : a position paper from the International Lipid Expert Panel (ILEP)

Author

Penson, Peter E., Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P., Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P., Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung-I, Mancini, G.B. John, von Haehling, Stephan, Banach, Maciej, Penson, Peter E., Bruckert, Eric, Marais, David, Reiner, Željko, Pirro, Matteo, Sahebkar, Amirhossein, Bajraktari, Gani, Mirrakhimov, Erkin, Rizzo, Manfredi, Mikhailidis, Dimitri P., Sachinidis, Alexandros, Gaita, Dan, Latkovskis, Gustavs, Mazidi, Mohsen, Toth, Peter P., Pella, Daniel, Alnouri, Fahad, Postadzhiyan, Arman, Yeh, Hung-I, Mancini, G.B. John, von Haehling, Stephan, and Banach, Maciej

Abstract

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3–5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)—what might be truth even for over 50% of all patients with muscle weakness/pain. Clear guidance is necessary to enable the optimal management of plasma in real-world clinical practice in patients who experience subjective AEs. In this Position Paper of the International Lipid Expert Panel (ILEP), we present a step-by-step patient-centred approach to the identification and management of SAMS with a particular focus on strategies to prevent and manage the nocebo/drucebo effect and to improve long-term compliance with lipid-lowering therapy.

Published
2022
Full Text
View/download PDF

37. Vascular Dysfunction of COVID-19 Is Partially Reverted in the Long-Term

Author

Zanoli, Luca, primary, Gaudio, Agostino, additional, Mikhailidis, Dimitri P., additional, Katsiki, Niki, additional, Castellino, Niccolò, additional, Lo Cicero, Lorenzo, additional, Geraci, Giulio, additional, Sessa, Concetto, additional, Fiorito, Letizia, additional, Marino, Francesca, additional, Antonietta Di Rosolini, Maria, additional, Colaci, Michele, additional, Longo, Antonio, additional, Montineri, Arturo, additional, Malatino, Lorenzo, additional, Castellino, Pietro, additional, Aparo, Paola, additional, Arena, Andrea, additional, Barchitta, Martina, additional, Castelletti, Federica, additional, Di Noto, Martina, additional, Di Pino, Antonino, additional, Giarrusso, Ornella, additional, Isaia, Ivan, additional, Lentini, Paolo, additional, Magnano San Lio, Paola, additional, Manuele, Rosa, additional, Marino, Elisa, additional, Morale, Walter, additional, Sciuto, Alice, additional, Scuto, Salvatore Sebastiano, additional, Xourafa, Anastasia, additional, and Zocco, Sabrina, additional

Published
2022
Full Text
View/download PDF

38. Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical Applications

Author

Manolis, Antonis A. Manolis, Theodora A. Melita, Helen and Mikhailidis, Dimitri P. Manolis, Antonis S.

Abstract

Cilostazol, a phosphodiesterase III inhibitor, has vasodilating and antiplatelet properties with a low rate of bleeding complications. It has been used over the past 25 years for improving intermittent claudication in patients with peripheral artery disease (PAD). Cilostazol also has demonstrated efficacy in patients undergoing percutaneous revascularization procedures for both PAD and coronary artery disease. In addition to its antithrombotic and vasodilating actions, cilostazol also inhibits vascular smooth muscle cell proliferation via phosphodiesterase III inhibition, thus mitigating restenosis. Accumulated evidence has shown that cilostazol, due to its “pleiotropic” effects, is a useful, albeit underutilized, agent for both coronary artery disease and PAD. It is also potentially useful after ischemic stroke and is an alternative in those who are allergic or intolerant to classical antithrombotic agents (eg, aspirin or clopidogrel). These issues are herein reviewed together with the pharmacology and pharmacodynamics of cilostazol. Large studies and meta-analyses are presented and evaluated. Current guidelines are also discussed, and the spectrum of cilostazol’s actions and therapeutic applications are illustrated.

Published
2022

39. Optimal Management of Asymptomatic Carotid Stenosis in 2021: The Jury is Still Out. An International, Multispecialty, Expert Review and Position Statement

Author

Paraskevas, Kosmas I. Mikhailidis, Dimitri P. Antignani, Pier Luigi Baradaran, Hediyeh Bokkers, Reinoud P. Cambria, Richard P. Dardik, Alan Davies, Alun H. Eckstein, Hans-Henning Faggioli, Gianluca Fernandes E Fernandes, Jose Fraedrich, Gustav Geroulakos, George Gloviczki, Peter Golledge, Jonathan Gupta, Ajay Jezovnik, Mateja K. Kakkos, Stavros K. Katsiki, Niki Knoflach, Michael Kooi, M. Eline Lanza, Gaetano Liapis, Christos D. Loftus, Ian M. Mansilha, Armando Millon, Antoine Nicolaides, Andrew N. Pini, Rodolfo Poredos, Pavel Ricco, Jean-Baptiste Riles, Thomas S. Ringleb, Peter Arthur Rundek, Tatjana Saba, Luca Schlachetzki, Felix Silvestrini, Mauro Spinelli, Francesco Stilo, Francesco Sultan, Sherif Suri, Jasjit S. Zeebregts, Clark J. Chaturvedi, Seemant

Abstract

Objectives: The recommendations of international guidelines for the management of asymptomatic carotid stenosis (ACS) often vary considerably and extend from a conservative approach with risk factor modification and best medical treatment (BMT) alone, to a more aggressive approach with a carotid intervention plus BMT. The aim of the current multispecialty position statement is to reconcile the conflicting views on the topic. Materials and methods: A literature review was performed with a focus on data from recent studies. Results: Several clinical and imaging high-risk features have been identified that are associated with an increased long-term ipsilateral ischemic stroke risk in patients with ACS. Such high-risk clinical/imaging features include intraplaque hemorrhage, impaired cerebrovascular reserve, carotid plaque echolucency/ulceration/ neovascularization, a lipid-rich necrotic core, a thin or ruptured fibrous cap, silent brain infarction, a contralateral transient ischemic attack/stroke episode, male patients < 75 years and microembolic signals on transcranial Doppler. There is growing evidence that 80-99% ACS indicate a higher stroke risk than 50-79% stenoses. Conclusions: Although aggressive risk factor control and BMT should be implemented in all ACS patients, several high-risk features that may increase the risk of a future cerebrovascular event are now documented. Consequently, some guidelines recommend a prophylactic carotid intervention in high-risk patients to prevent future cerebrovascular events. Until the results of the much-anticipated randomized controlled trials emerge, the jury is still out regarding the optimal management of ACS patients. (c) 2021 Elsevier Inc. All rights reserved.

Published
2022

40. The burden of carotid-related strokes

Author

Paraskevas, Kosmas I., primary, Mikhailidis, Dimitri P., additional, Baradaran, Hediyeh, additional, Bokkers, Reinoud P. H., additional, Davies, Alun H., additional, Eckstein, Hans-Henning, additional, Faggioli, Gianluca, additional, Fernandes, Jose Fernandes E, additional, Gargiulo, Mauro, additional, Jawien, Arkadiusz, additional, Jezovnik, Mateja K., additional, Kakkos, Stavros K., additional, Knoflach, Michael, additional, Kooi, M. Eline, additional, Lanza, Gaetano, additional, Liapis, Christos D., additional, Loftus, Ian M., additional, Mansilha, Armando, additional, Mechtouff, Laura, additional, Millon, Antoine, additional, Myrcha, Piotr, additional, Nicolaides, Andrew N., additional, Pini, Rodolfo, additional, Poredos, Pavel, additional, Ricco, Jean-Baptiste, additional, Rundek, Tatjana, additional, Saba, Luca, additional, Silvestrini, Mauro, additional, Spinelli, Francesco, additional, Stilo, Francesco, additional, Sultan, Sherif, additional, Suri, Jasjit S., additional, Svetlikov, Alexei V., additional, Wijeratne, Tissa, additional, Zeebregts, Clark J., additional, and Gloviczki, Peter, additional

Published
2022
Full Text
View/download PDF

41. Optimal Management of Asymptomatic Carotid Stenosis: Counterbalancing the Benefits with the Potential Risks

Author

Paraskevas, Kosmas I., primary, Mikhailidis, Dimitri P., additional, Baradaran, Hediyeh, additional, Davies, Alun H., additional, Eckstein, Hans-Henning, additional, Faggioli, Gianluca, additional, Fernandes, Jose Fernandes e, additional, Gupta, Ajay, additional, Jezovnik, Mateja K., additional, Kakkos, Stavros K., additional, Katsiki, Niki, additional, Kooi, M. Eline, additional, Lanza, Gaetano, additional, Liapis, Christos D., additional, Loftus, Ian M., additional, Millon, Antoine, additional, Nicolaides, Andrew N., additional, Poredos, Pavel, additional, Pini, Rodolfo, additional, Ricco, Jean-Baptiste, additional, Rundek, Tatjana, additional, Saba, Luca, additional, Spinelli, Francesco, additional, Stilo, Francesco, additional, Sultan, Sherif, additional, Zeebregts, Clark J., additional, and Chaturvedi, Seemant, additional

Published
2022
Full Text
View/download PDF

42. Glucagon-Like Peptide-1 Receptor Agonists and Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonists in the Treatment of Obesity/Metabolic Syndrome, Prediabetes/Diabetes and Non-Alcoholic Fatty Liver Disease—Current Evidence

Author

Muzurović, Emir M., primary, Volčanšek, Špela, additional, Tomšić, Karin Zibar, additional, Janež, Andrej, additional, Mikhailidis, Dimitri P., additional, Rizzo, Manfredi, additional, and Mantzoros, Christos S., additional

Published
2022
Full Text
View/download PDF

43. Relationship Between Anti-DFS70 Autoantibodies and Oxidative Stress

Author

Krzemień, Paweł, primary, Kasperczyk, Sławomir, additional, Banach, Maciej, additional, Kasperczyk, Aleksandra, additional, Dobrakowski, Michał, additional, Tomasik, Tomasz, additional, Windak, Adam, additional, Mastej, Mirosław, additional, Catapano, Alberico, additional, Ray, Kausik K, additional, Mikhailidis, Dimitri P, additional, Toth, Peter P, additional, Howard, George, additional, Lip, Gregory YH, additional, Tomaszewski, Maciej, additional, Charchar, Fadi J, additional, Sattar, Naveed, additional, Williams, Bryan, additional, MacDonald, Thomas M, additional, Penson, Peter E, additional, Jóźwiak, Jacek J, additional, Al-Shaer, B., additional, Andrusewicz, W., additional, Andrzejczuk-Rosa, M., additional, Anusz-Gaszewska, E., additional, Bagińska, A., additional, Balawajder, P., additional, Bańka, G., additional, Barańska-Skubisz, E., additional, Barbara Przyczyna, B., additional, Bartkowiak, S., additional, Bartodziej, J., additional, Bartosiewicz, M., additional, Basałyga, M., additional, Batyra, A., additional, Bąk, A., additional, Bednarz, M., additional, Bejnar, K., additional, Bernacki, W., additional, Betiuk-Kwiatkowska, M., additional, Biegaj, S., additional, Bień, M., additional, Bilski, W., additional, Biłogan, M., additional, Biruta-Pawłowska, G., additional, Biskup, A., additional, Błaszczyk, B., additional, Błaszczyk, H., additional, Błońska-Jankowska, T., additional, Bogacka-Gancarczyk, B., additional, Bojanowska, M., additional, Bonda, E., additional, Borowik-Skwarek, J., additional, Borowska, J., additional, Bruckner, J., additional, Brzostek, J., additional, Brzuchacz, M., additional, Budzyńska, M., additional, Bulzacka-Fugiel, I., additional, Bulzak, J., additional, Bunikowski, K., additional, Cebulska, A., additional, Celka, T., additional, Cempel-Nowak, E., additional, Chechliński, W., additional, Chludzińska, A., additional, Chmiel, D., additional, Chmielewska, M., additional, Cichy, M., additional, Ciemięga, A., additional, Ciepluch, A., additional, Cieszyńska, I., additional, Czajka, B., additional, Czapla, B., additional, Czerner, M., additional, Czerwińska, B., additional, Czuryszkiewicz, W., additional, Daleka, E., additional, Dawid, Z., additional, Dąbrowska, M., additional, Dąbrowska, R., additional, Dąbrowski, D., additional, Dąbrowski, M., additional, Demczyszyn, K., additional, Dębowska-Serwińska, A., additional, Dmochowski, J., additional, Dobrzecka-Kiwior, J., additional, Dolanowska, E., additional, Dolanowski, H., additional, Dołek, P., additional, Domagała, M., additional, Domański, H., additional, Doszel, A., additional, Duda, D., additional, Dudkowska, M., additional, Dudziuk, B., additional, Dybciak, P., additional, Dymanowski, M., additional, Dziadzio-Bolek, L., additional, Eicke, M., additional, El-Hassan, H., additional, Eremus, A., additional, Fąferek-Muller, M., additional, Figura-Roguska, E., additional, Fijałkowska-Kaczmarek, I., additional, Flis, M., additional, Florczak, T., additional, Florczuk, M., additional, Foryszewska-Witan, E., additional, Frydrych, W., additional, Fugiel, A., additional, Futyma, E., additional, Gaca-Jaroszewicz, A., additional, Gajdamowicz, I., additional, Ganczarski, K., additional, Gatnar, A., additional, Gers, M., additional, Głowacki, A., additional, Głód, K., additional, Godula, J., additional, Gołąb, J., additional, Gołębiewski, M., additional, Goszczyńska, E., additional, Gościcka, K., additional, Górna-Hajduga, A., additional, Górny, E., additional, Grabowska, T., additional, Grabowski, R., additional, Graczyk-Duda, A., additional, Gromow, A., additional, Grudewicz, A., additional, Gruszecka, J., additional, Gruszka, A., additional, Gryboś, J., additional, Grzebyk, J., additional, Grzechowiak, A., additional, Grzesiak, D., additional, Grześkowiak, T., additional, Guźla, A., additional, Hachuła, G., additional, Hawel, B., additional, Hiltawska, H., additional, Honkowicz, E., additional, Ignatowicz, J., additional, Imielski, K., additional, Iwaniura, A., additional, Jagieła-Szymala, A., additional, Jalć-Sowała, M., additional, Janczylik, A., additional, Janisz, E., additional, Janiszek, M., additional, Jankiewicz-Ziobro, K., additional, Januszewska, K., additional, Jaremek, A., additional, Jaros-Urbaniak, A., additional, Jarosz, J., additional, Jarosz, P., additional, Jasiński, W., additional, Jezierska-Wasilewska, M., additional, Jędraszewski, T., additional, Jędrzejowska, A., additional, Józefowicz, R., additional, Juźwin, K., additional, Kacprzak, E., additional, Kaczmarek-Szewczyk, J., additional, Kaczmarzyk, M., additional, Kandziora, R., additional, Kaniewski, C., additional, Karolak-Brandt, L., additional, Kasperczyk, S., additional, Kasperek-Dyląg, E., additional, Kedziora, I., additional, Kępa, A., additional, Kiciński, J., additional, Kielak-Al-Hosam, J., additional, Kiełczawa, Ł., additional, Kilimowicz, P., additional, Kitliński, K., additional, Kiwka, T., additional, Klein, U., additional, Klichowicz, L., additional, Klimowicz, A., additional, Klonowski, B., additional, Kmolek, B., additional, Kobyłko-Klepacka, E., additional, Kocoń, A., additional, Kolenda, A., additional, Kollek, E., additional, Kopeć, M., additional, Koper-Kozikowska, B., additional, Koralewska, J., additional, Korczyńska, M., additional, Korzeniewski, M. T., additional, Kosk, A., additional, Kotarski, K., additional, Kowalczyk, E., additional, Kowalczyk, M., additional, Kowalik, I., additional, Kozak-Błażkiewicz, B., additional, Kozik, M., additional, Kozłowska, D., additional, Kozłowska, E., additional, Kozłowska, M., additional, Kozubski, T., additional, Kózka, K., additional, Kraśnik, L., additional, Krężel, T., additional, Krochmal, B., additional, Król, B., additional, Król, G., additional, Król, J., additional, Królikowska, T., additional, Kruszewska, H., additional, Krygier-Potrykus, B., additional, Krystek, W., additional, Krzysztoń, J., additional, Kubicki, T., additional, Kuczmierczyk-El-Hassan, A., additional, Kuczyńska-Witek, W., additional, Kujda, D., additional, Kurowski, A., additional, Kurzelewska-Solarz, I., additional, Kwaczyńska, M., additional, Kwaśniak, M., additional, Kwaśniak, P., additional, Kwietniewska, T., additional, Łebek-Ordon, A., additional, Lebiedowicz, A., additional, Lejkowska-Olszewska, L., additional, Lentas, M., additional, Lesiewicz-Ksycińska, A., additional, Limanowski, M., additional, Łoniewski, S., additional, Łopata, J. A., additional, Łubianka, B., additional, Łukasiuk, I., additional, Łużna, M., additional, Łysiak, M., additional, Łysik, B., additional, Machowski, Z., additional, Maciaczyk-Kubiak, J., additional, Mackiewicz-Zabochnicka, G., additional, Magner-Krężel, Z., additional, Majda, S., additional, Malinowski, P., additional, Mantyka, J., additional, Marchlik, E., additional, Martyna-Ordyniec, G., additional, Marzec, J., additional, Marzec, M., additional, Matejko-Wałkiewicz, R., additional, Mazur, M., additional, Michalczak, M., additional, Michalska-Żyłka, A., additional, Michniewicz, M., additional, Mika-Staniszewska, D., additional, Mikiciuk, E., additional, Mikołajczak, T., additional, Milewski, J., additional, Miller, E., additional, Misiaszek, B., additional, Mizik-Łukowska, M., additional, Młyńczyk-Pokutycka, E., additional, Mocek, M., additional, Moczała, M., additional, Morawska-Hermanowicz, M., additional, Moryc, P., additional, Moskal, A., additional, Moskal, S., additional, Moździerz, A., additional, Moździerz, P., additional, Mrozińska, M., additional, Mrozowicz, K., additional, Mróz, G., additional, Munia, T., additional, Mura, A., additional, Muras-Skudlarska, M., additional, Murawska, E. Z., additional, Murawski, Ł., additional, Murawski, R., additional, Musielak, R., additional, Nadaj, K., additional, Nagarnowicz, W., additional, Napierała, R., additional, Niedźwiecka, M., additional, Niemirski, A., additional, Nikiel, J., additional, Nosal, M., additional, Nowacki, W., additional, Nowak, J., additional, Nyrka, M., additional, Obst, A., additional, Ochowicz, J., additional, Ogonowska, E., additional, Oleszczyk, M., additional, Ołdakowski, A., additional, Ołowniuk-Stefaniak, I., additional, Ordowska-Rejman, J., additional, Orliński, M., additional, Osińska, B., additional, Ostańska-Burian, A., additional, Paciorkowska, A., additional, Paczkowska, U., additional, Paluch, L., additional, Pałka, L., additional, Paszko-Wojtkowska, J., additional, Paszkowska, A., additional, Pawlak-Ganczarska, E., additional, Pawlik, W., additional, Pawłowska, I., additional, Paździora, M., additional, Permiakow, G., additional, Petlic-Marendziak, A., additional, Piasecka, T., additional, Piaścińska, E., additional, Piktel, A., additional, Pilarska-Igielska, A., additional, Piotrkowska, A., additional, Piwowar-Klag, K., additional, Planer, M., additional, Plewa, J., additional, Płatkiewicz, P., additional, Płonczyńska, B., additional, Podgórska, A., additional, Polewska, M., additional, Porębska, B., additional, Porwoł, P., additional, Potakowska, I., additional, Prokop, A., additional, Przybylski, J., additional, Przybyła, M., additional, Psiuk, H., additional, Ptak, K., additional, Puzoń, G., additional, Rabiza, N., additional, Rachwalik, S., additional, Raczyńska, E., additional, Raniszewska, M., additional, Romanek-Kozik, A., additional, Rosa, A., additional, Rosa, K., additional, Rozewicz, A., additional, Rudzka-Kałwak, J., additional, Rusak, J., additional, Rutkowska, D., additional, Rybacki, M., additional, Rybińska, D., additional, Rycyk-Sadowska, A., additional, Rynda, L., additional, Rynkiewicz, B., additional, Sadowska-Krawczyk, B., additional, Sadowska-Zarzycka, M., additional, Sarnecka, B., additional, Sawalach-Tomanik, E., additional, Sidor-Drozd, B., additional, Siemieniak-Dębska, M., additional, Sieroń, A., additional, Siewniak-Zalewska, B., additional, Sikora, A., additional, Sitarska-Pawlina, B., additional, Skorupski, J., additional, Skrzypińska-Mansfeld, I., additional, Skubisz, J., additional, Skwarek, R., additional, Słodyczka, M., additional, Smentek, M., additional, Smolińska, K., additional, Solarz, B., additional, Sosnowska, W., additional, Sroka, B., additional, Stachura, H., additional, Stangreciak, D., additional, Staniak, M., additional, Stańczyk, Z., additional, Stańszczak-Ozga, D., additional, Startek, E., additional, Stefańczyk, M., additional, Stelmach, R., additional, Sternadel-Rączka, E., additional, Sternik, M., additional, Stępień, J., additional, Stocka, J., additional, Stokowska-Wojda, M., additional, Studler-Karpińska, M., additional, Suchorukow, W., additional, Sufryd, W., additional, Supłacz, B., additional, Sygacz, J., additional, Szczepański, Ł., additional, Szkandera, J., additional, Szłapa-Zellner, J., additional, Szydlarska, D., additional, Śliwa, T., additional, Śliwka, J., additional, Śmiejkowski, Ł., additional, Targońska, A., additional, Tesarska, E., additional, Tobiasz, M., additional, Tomaka, J., additional, Tomalska-Bywalec, K., additional, Tomiak, E., additional, Topczewski, S., additional, Trawińska, A., additional, Trela-Mucha, L., additional, Trojanowski, D., additional, Trzaskowska, M., additional, Trzcińska-Larska, B., additional, Trznadel-Mozul, A., additional, Ulanicka-Liwoch, K., additional, Urbanowicz, M., additional, Uthke-Kluzek, A., additional, Waczyński, J., additional, Walczak, J., additional, Warsz, L., additional, Wasyńczuk, M., additional, Wąchała-Jędras, U., additional, Wąsowicz, D., additional, Wczysła, J., additional, Wenda, F., additional, Werner-Kubicka, E., additional, Weryszko, E., additional, Węgrzynowska, B., additional, Wiaksa, M., additional, Wiankowski, M., additional, Wicherek, A., additional, Wieczorek, R., additional, Wiencek, R., additional, Wienzek-Tatara, G., additional, Wierzbicka, B., additional, Wierzbicki, M., additional, Wilczyńska, B., additional, Wilmańska, D., additional, Winiarski, P., additional, Wiszniewska-Pabiszczak, A., additional, Witkowska, M. B., additional, Witzling, J., additional, Wlaź, A., additional, Wojtkowiak, I., additional, Woydyłło, J., additional, Woźniak, K., additional, Wójtowicz, A., additional, Wrona, J., additional, Wrońska, M., additional, Wujkowska, H., additional, Wyrąbek, J., additional, Wysokiński, O., additional, Zakrzewski, R., additional, Zaleska-Zatkalik, J., additional, Zaleski, J., additional, Zalewska-Dybciak, M., additional, Zalewska, E., additional, Zalewska-Uchimiak, B., additional, Zawadzka-Krajewska, J., additional, Zawadzki, J., additional, Zieliński, A., additional, Zubrycka, E., additional, Żybort, I., additional, and Żymełka, M., additional

Published
2022
Full Text
View/download PDF

48. Serum antinuclear autoantibodies are associated with measures of oxidative stress and lifestyle factors: analysis of LIPIDOGRAM2015 and LIPIDOGEN2015 studies

Author

Krzemień, Paweł, primary, Kasperczyk, Sławomir, additional, Banach, Maciej, additional, Kasperczyk, Aleksandra, additional, Dobrakowski, Michał, additional, Tomasik, Tomasz, additional, Windak, Adam, additional, Mastej, Mirosław, additional, Catapano, Alberico, additional, Ray, Kausik K., additional, Mikhailidis, Dimitri P., additional, Toth, Peter P., additional, Howard, George, additional, Lip, Gregory Y. H., additional, Tomaszewski, Maciej, additional, Charchar, Fadi J., additional, Sattar, Naveed, additional, Williams, Bryan, additional, MacDonald, Thomas M., additional, Penson, Peter E., additional, and Jóźwiak, Jacek J., additional

Published
2021
Full Text
View/download PDF

50. The impact of type of dietary protein, animal versus vegetable, in modifying cardiometabolic risk factors: a position paper from the International Lipid Expert Panel (ILEP)

Author

Zhubi-Bakija, Fjolla, Bajraktari, Gani, Bytyçi, Ibadete, Mikhailidis, Dimitri P., Henein, Michael Y., Latkovskis, Gustavs, Rexhaj, Zarife, Zhubi, Esra, Banach, Maciej, Stefanutti, Claudia, Alnouri, Fahad, Amar, Fahma, Atanasov, Atanas G., Bartlomiejczyk, Marcin A., Bjelakovic, Bojko, Bruckert, Eric, Cafferata, Alberto, Ceska, Richard, Cicero, Arrigo F.G., Collet, Xavier, Descamps, Olivier, Djuric, Dragan, Durst, Ronen, Ezhov, Marat V., Fras, Zlatko, Gaita, Dan, Hernandez, Adrian V., Jones, Steven R., Jozwiak, Jacek, Kakauridze, Nona, Katsiki, Niki, Khera, Amit, Kostner, Karam, Kubilius, Raimondas, Mancini, G.B. John, Marais, A. David, Martin, Seth S., Martinez, Julio Acosta, Mazidi, Mohsen, Mirrakhimov, Erkin, Miserez, Andre R., Mitchenko, Olena, Moriarty, Patrick M., Nabavi, Seyed Mohammad, Nair, Devaki, Panagiotakos, Demosthenes B., Paragh, György, Pella, Daniel, Penson, Peter E., Petrulionienė, Žaneta, Pirro, Matteo, Postadzhiyan, Arman, Puri, Raman, Reda, Ashraf, Reiner, Željko, Riadh, Jemaa, Richter, Dimitri, Rizzo, Manfredi, Ruscica, Massimiliano, Sahebkar, Amirhossein, Sattar, Naveed, Serban, Maria-Corina, Shehab, Abdulla M.A., Shek, Aleksandr B., Sirtori, Cesare R., Tomasik, Tomasz, Toth, Peter P., Viigimaa, Margus, Vinereanu, Dragos, Vohnout, Branislav, von Haehling, Stephan, Vrablik, Michal, Wong, Nathan D., Yeh, Hung-I., Zhisheng, Jiang, and Zirlik, Andreas

Subjects
cardiovascular disease, cholesterol, dietary protein, metabolic syndrome, weight loss, food and beverages
Abstract

Proteins play a crucial role in metabolism, in maintaining fluid and acid-base balance and antibody synthesis. Dietary proteins are important nutrients and are classified into: 1) animal proteins (meat, fish, poultry, eggs and dairy), and, 2) plant proteins (legumes, nuts and soy). Dietary modification is one of the most important lifestyle changes that has been shown to significantly decrease the risk of cardiovascular (CV) disease (CVD) by attenuating related risk factors. The CVD burden is reduced by optimum diet through replacement of unprocessed meat with low saturated fat, animal proteins and plant proteins. In view of the available evidence, it has become acceptable to emphasize the role of optimum nutrition to maintain arterial and CV health. Such healthy diets are thought to increase satiety, facilitate weight loss, and improve CV risk. Different studies have compared the benefits of omnivorous and vegetarian diets. Animal protein related risk has been suggested to be greater with red or processed meat over and above poultry, fish and nuts, which carry a lower risk for CVD. In contrast, others have shown no association of red meat intake with CVD. The aim of this expert opinion recommendation was to elucidate the different impact of animal vs vegetable protein on modifying cardiometabolic risk factors. Many observational and interventional studies confirmed that increasing protein intake, especially plant-based proteins and certain animal-based proteins (poultry, fish, unprocessed red meat low in saturated fats and low-fat dairy products) have a positive effect in modifying cardiometabolic risk factors. Red meat intake correlates with increased CVD risk, mainly because of its non-protein ingredients (saturated fats). However, the way red meat is cooked and preserved matters. Thus, it is recommended to substitute red meat with poultry or fish in order to lower CVD risk. Specific amino acids have favourable results in modifying major risk factors for CVD, such as hypertension. Apart from meat, other animal-source proteins, like those found in dairy products (especially whey protein) are inversely correlated to hypertension, obesity and insulin resistance.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results